Evaluation of the Public Health Impact of Seasonal Intermittent Preventive Treatment (IPT) in Children in Senegal

Sponsor
London School of Hygiene and Tropical Medicine (Other)
Overall Status
Unknown status
CT.gov ID
NCT00712374
Collaborator
Senegal: Ministere de la Sante (Other), Institut de Recherche pour le Developpement (Other), Cheikh Anta Diop University, Senegal (Other)
100,000
1
46

Study Details

Study Description

Brief Summary

In areas of seasonal malaria transmission the burden of severe disease and mortality due to malaria is mainly among children under 5 years of age. Intermittent preventive treatment (IPT) with antimalarial drugs given to all children once a month during the transmission season is a promising new strategy for malaria prevention. Studies in Senegal, Ghana, Mali and The Gambia have shown this approach can be highly effective. In Senegal, seasonal IPT with sulfadoxine-pyrimethamine (SP) and one dose of artesunate resulted in a 90% reduction in incidence of clinical malaria in a recent trial in Senegal (Cisse et al., Lancet 2006). The purpose of the present project is to determine the public health impact and cost effectiveness of this intervention when it is delivered through the routine health service to communities in rural areas in Senegal. Demographic surveillance will be set up in the rural population of three districts (Mbour, Bambey and Fatick) which comprises approximately 540,000 people, including 100,000 children under 5 yrs, and is served by 54 health posts, as an expansion of the area covered by the existing DSS of Niakhar. Information about births, deaths and migrations, household characteristics such as socioeconomic status, and vaccination status of children and their use of bednets, will be recorded in 6-monthly rounds of all households. In selected areas, deaths among children under 10 years will be investigated using verbal autopsies. Over four years from September 2008 - November 2011, seasonal IPT (three monthly administrations of SP (sulfalene-pyrimethamine) plus amodiaquine during the transmission season each year to children 3-59 months of age) will be introduced gradually, in a step-wedge design, by 9 health posts in 2008, by an additional 18 posts in 2009, and another 18 in 2010 and 9 in 2011. At the end of each transmission season, a cross-sectional survey of 2400 children under 5 yrs of age, in which finger prick blood samples will be taken, will be used to estimate the prevalence of molecular markers of drug resistance to Plasmodium falciparum, the prevalence of anaemia and the nutritional status of children. Malaria incidence will be monitored by passive surveillance through health posts, health centres, and hospitals. Cost effectiveness will be assessed. Due to changes in the epidemiology of malaria in the study area, the upper age limit for inclusion was increased from 5 to 10 years old from September 2009.

Condition or Disease Intervention/Treatment Phase
  • Drug: sulfadoxine-pyrimethamine plus amodiaquine
Phase 4

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100000 participants
Allocation:
Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Evaluation of the Public Health Impact and Cost Effectiveness of Seasonal Intermittent Preventive Treatment in Children in Senegal
Study Start Date :
Sep 1, 2008
Anticipated Primary Completion Date :
Dec 1, 2011
Anticipated Study Completion Date :
Jul 1, 2012

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention

Children 3 months to 10 years old will receive a treatment dose of SP+AQ on three occasions during the malaria transmission season, delivered by the local health post

Drug: sulfadoxine-pyrimethamine plus amodiaquine
SP+AQ on three occasions during the malaria transmission season Intermittent Preventive Treatment with sulfadoxine-pyrimethamine plus amodiaquine

Outcome Measures

Primary Outcome Measures

  1. All-causes mortality [2008-2010]

Secondary Outcome Measures

  1. Incidence of malaria by passive case detection [2008-2010]

Eligibility Criteria

Criteria

Ages Eligible for Study:
3 Months to 119 Months
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Age 3-119 months at time of first administration of IPT in September

  • Consent of mother or carer and the local community

Exclusion Criteria:
  • History of allergy to SP or AQ

  • Age < 3 months or >119 months at time of first administration of IPT in September

From 2009, the age for inclusion has been changed from 3-59 months to 3 months to 10 years of age.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • London School of Hygiene and Tropical Medicine
  • Senegal: Ministere de la Sante
  • Institut de Recherche pour le Developpement
  • Cheikh Anta Diop University, Senegal

Investigators

  • Study Director: Oumar Gaye, PhD, Universite CHeikh Anta Diop
  • Principal Investigator: Badara Cisse, PhD, London School of Hygiene and Tropical Medicine
  • Principal Investigator: Cheikh Sokhna, PhD, IRD, Dakar
  • Principal Investigator: Oumar Faye, MD, Ministere de la Sante et de la Prevention
  • Principal Investigator: Paul Milligan, PhD, London School of Hygiene and Tropical Medicine

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00712374
Other Study ID Numbers:
  • PSP01
  • 40099
First Posted:
Jul 10, 2008
Last Update Posted:
Sep 22, 2009
Last Verified:
Sep 1, 2009

Study Results

No Results Posted as of Sep 22, 2009